-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51

Benzinga·11/02/2026 09:48:12
Listen to the news
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $50 to $51.